UA126950U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis includes clinical examination, studies of low and high density lipoprotein cholesterol levels, arteriography, determination of MTHFR C677T, eNOS T786C gene polymorphism, osteocalcin content, TGF-7, TGM-78, 1, 78 SS, osteocalcin levels <21 ng / ml, TGF- (1 <14 ng / ml, COMP> 595 ng / ml diagnose the development of atherosclerosis.

Description

The proposed method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of low- and high-density lipoprotein cholesterol levels, arteriography (A.N. Okorokov.

Diagnosis of diseases of internal organs. -T. 6-S. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that, along with the study of low and high-density lipoprotein cholesterol levels, arteriography in the patient's blood serum determines the polymorphism of the genes methylenetetrahydrofolate reductase (MINEK C677T), nitric oxide synthase (emoz 1T786C), the content of osteocalcin, transforming growth factor beta 1 (TGF- RDI1), cartilaginous oligomeric matrix prosthesis (SOMR). With homozygous carrier 677-177, 786-SS, levels of osteocalcin "21 ng/ml, TFR-DI "14 ng/ml, SOMR "595 ng/ml diagnose the development of atherosclerosis.

Application of the method. During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. Polymorphisms of MTNEK C677T, emMmo5 T7786C genes are determined in blood serum, osteocalcin content, TGF-VII, and SOMR are determined by immunoenzymatic method. With homozygous carriers of 677-HTT, 786-SS, levels of osteocalcin "21 ng/ml, TFR-B1I "14 ng/ml, SOMR "595 ng/ml, the development of atherosclerosis is diagnosed.

A specific example of using the method.

Patient 3., 46 years old, hospitalized in the clinic with a diagnosis of rheumatoid arthritis. Examined

Low and high density lipoprotein cholesterol levels were studied. An arteriography of vessels was performed. No signs of atherosclerosis were found. Gene polymorphism was determined in blood serum

MTNEV S677T and emoz 1T786S. The content of osteocalcin was determined by the immunoenzymatic method,

From TFR-DV1I, SOMR. Homozygous carriers of 677-171 and 786-SS were established. Levels of osteocalcin - 15 ng/ml, TFR-B1I - 8.4 ng/ml, SOMR - 648 ng/ml. The development of atherosclerosis was diagnosed.

Arteriographic confirmation of the diagnosis was obtained only after 12 months.

Thus, the proposed method is useful and allows establishing a diagnosis at an early date.

Claims (1)

USEFUL MODEL FORMULA A method of diagnosing the development of atherosclerosis, which includes a clinical examination, a study of low and high-density lipoprotein cholesterol levels, arteriography, which is distinguished by which additionally determine the polymorphism of the MINEV C677T, eMMO5 T7860 genes in the blood serum, the content of osteocalcin, TFR-D1, SOMP, and with homozygous carriers of 677-TT, 786-SS, levels of osteocalcin "21 ng/ml, TFR-D1 "14 ng/ml , SOMR »595 ng/ml diagnose the development of atherosclerosis.